• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.小鼠对约氏疟原虫裂殖子表面蛋白1的19千道尔顿羧基末端片段产生持久的保护性免疫反应。
Clin Vaccine Immunol. 2007 Apr;14(4):342-7. doi: 10.1128/CVI.00397-06. Epub 2007 Feb 21.
2
A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice.单次注射用 Montanide ISA 和 CpG ODN 配制的疟原虫 yoelii 裂殖子表面蛋白 1(PyMSP1(19))的 19 kDa 羧基末端片段在小鼠中诱导保护性免疫应答。
Asian Pac J Allergy Immunol. 2011 Sep;29(3):252-9.
3
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.CpG 寡脱氧核苷酸可增强用酵母表达的约氏疟原虫裂殖子表面蛋白 1(MSP1(19))的 19 kDa 羧基末端片段经油基 Montanides 配制后对小鼠进行肠胃外免疫时针对血液期疟疾感染的免疫力。
Vaccine. 2003 Jun 20;21(21-22):2923-32. doi: 10.1016/s0264-410x(03)00132-4.
4
Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.用在酿酒酵母中表达的约氏疟原虫裂殖子表面蛋白-1(MSP1[19])的19千道尔顿羧基末端片段免疫小鼠诱导产生的完全保护性免疫:保护作用与抗原特异性抗体滴度相关,但与效应性CD4+T细胞无关。
J Immunol. 1997 Oct 1;159(7):3400-11.
5
Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.含恶性疟原虫裂殖子表面蛋白-1 羧基端 19 kDa 片段和鼠伤寒沙门氏菌鞭毛蛋白 FliC 天然免疫激动剂的重组融合蛋白的免疫原性。
Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004. Epub 2010 Feb 17.
6
New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.基于间日疟原虫裂殖子表面蛋白-1和TLR-5激动剂鼠伤寒沙门氏菌鞭毛蛋白FliC的新型疟疾疫苗候选物。
Vaccine. 2008 Nov 11;26(48):6132-42. doi: 10.1016/j.vaccine.2008.08.070. Epub 2008 Sep 18.
7
Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.基于约氏疟原虫(一种啮齿类疟原虫)裂殖子表面蛋白-1的DNA疫苗和蛋白质疫苗引发的体液免疫反应比较。
J Immunol. 1998 Oct 15;161(8):4211-9.
8
Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.对于通过针对裂殖子表面蛋白-1的19-kDa羧基末端片段的抗体被动获得的约氏疟原虫免疫力而言,涉及B细胞和Th细胞的活跃免疫反应的绝对需求。
J Immunol. 1999 Jun 15;162(12):7309-14.
9
Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.聚合物微粒和Montanide ISA 720对小鼠恶性疟原虫MSP2长合成肽免疫反应的佐剂活性
Vaccine. 2007 Jan 15;25(5):877-85. doi: 10.1016/j.vaccine.2006.09.036. Epub 2006 Sep 20.
10
Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.在鼠疟疫苗模型中,通过添加寡脱氧核苷酸和氢氧化铝凝胶提高重组19千道尔顿裂殖子表面蛋白1的免疫原性和效力。
Infect Immun. 2002 Feb;70(2):692-701. doi: 10.1128/IAI.70.2.692-701.2002.

引用本文的文献

1
Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity.自组装蛋白质纳米颗粒上抗原展示的方向影响免疫原性。
Vaccines (Basel). 2021 Jan 29;9(2):103. doi: 10.3390/vaccines9020103.
2
Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection.用MAEBL M2结构域进行免疫可抵御致死性约氏疟原虫感染。
Infect Immun. 2015 Oct;83(10):3781-92. doi: 10.1128/IAI.00262-15. Epub 2015 Jul 13.
3
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.嵌合疟原虫裂殖子表面蛋白疫苗诱导高滴度的寄生虫生长抑制抗体。
Infect Immun. 2013 Oct;81(10):3843-54. doi: 10.1128/IAI.00522-13. Epub 2013 Jul 29.
4
Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.自身相关聚集物和化学交联的疟原虫裂殖子表面蛋白 1 42kDa 片段的免疫原性。
PLoS One. 2012;7(6):e36996. doi: 10.1371/journal.pone.0036996. Epub 2012 Jun 4.
5
The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.通过预先接种重组腺病毒,可以克服增强蛋白疫苗免疫原性和保护效力所需的强效佐剂的要求。
J Immunol. 2011 Sep 1;187(5):2602-16. doi: 10.4049/jimmunol.1101004. Epub 2011 Aug 3.
6
Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.免疫接种嵌合血期疟原虫疫苗引起的保护性免疫应答持续存在,但不会因约氏疟原虫感染挑战而增强。
Vaccine. 2010 Oct 4;28(42):6876-84. doi: 10.1016/j.vaccine.2010.08.018. Epub 2010 Aug 13.
7
Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.嵌合重组构建体中自体 T 细胞表位的遗传连锁提高了疟疾候选疫苗的抗寄生虫和抗疾病保护效果。
Vaccine. 2010 Mar 19;28(14):2580-92. doi: 10.1016/j.vaccine.2010.01.019. Epub 2010 Jan 22.

本文引用的文献

1
Plasmodium yoelii can ablate vaccine-induced long-term protection in mice.约氏疟原虫可消除疫苗诱导的小鼠长期保护作用。
J Immunol. 2005 Aug 15;175(4):2510-6. doi: 10.4049/jimmunol.175.4.2510.
2
The global distribution of clinical episodes of Plasmodium falciparum malaria.恶性疟原虫疟疾临床发作的全球分布情况。
Nature. 2005 Mar 10;434(7030):214-7. doi: 10.1038/nature03342.
3
Vaccine-induced immunity to malaria parasites and the need for novel strategies.疫苗诱导的针对疟原虫的免疫力及新型策略的必要性。
Trends Parasitol. 2005 Jan;21(1):29-34. doi: 10.1016/j.pt.2004.10.006.
4
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.CPG 7909,一种免疫刺激型Toll样受体9激动剂寡脱氧核苷酸,作为健康成年人中乙肝疫苗(安在时)的佐剂:一项双盲I/II期研究。
J Clin Immunol. 2004 Nov;24(6):693-701. doi: 10.1007/s10875-004-6244-3.
5
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.WT1(威尔姆斯瘤基因)肽疫苗诱导WT1特异性细胞毒性T淋巴细胞及由此导致的癌症消退。
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90. doi: 10.1073/pnas.0405884101. Epub 2004 Sep 13.
6
CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.CpG寡脱氧核苷酸与Montanide ISA 51佐剂联合使用可增强亚单位疟疾疫苗的保护效果。
Infect Immun. 2004 Feb;72(2):949-57. doi: 10.1128/IAI.72.2.949-957.2004.
7
Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice.用新型免疫刺激佐剂对小鼠进行血液期疟疾疫苗接种。
Infect Immun. 2003 Sep;71(9):5178-87. doi: 10.1128/IAI.71.9.5178-5187.2003.
8
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.CpG 寡脱氧核苷酸可增强用酵母表达的约氏疟原虫裂殖子表面蛋白 1(MSP1(19))的 19 kDa 羧基末端片段经油基 Montanides 配制后对小鼠进行肠胃外免疫时针对血液期疟疾感染的免疫力。
Vaccine. 2003 Jun 20;21(21-22):2923-32. doi: 10.1016/s0264-410x(03)00132-4.
9
Parasite-specific immunoglobulin isotypes during lethal and non-lethal murine malaria infections.致死性和非致死性小鼠疟疾感染期间的寄生虫特异性免疫球蛋白亚型
Parasitol Res. 2003 Jan;89(1):26-33. doi: 10.1007/s00436-002-0687-3. Epub 2002 Aug 24.
10
Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.用约氏疟原虫裂殖子表面蛋白1的19千道尔顿片段免疫的小鼠在攻毒后产生的所需保护性免疫反应的性质和特异性。
Infect Immun. 2002 Nov;70(11):6013-20. doi: 10.1128/IAI.70.11.6013-6020.2002.

小鼠对约氏疟原虫裂殖子表面蛋白1的19千道尔顿羧基末端片段产生持久的保护性免疫反应。

Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.

作者信息

Jeamwattanalert Pimmada, Mahakunkijcharoen Yuvadee, Kittigul Leera, Mahannop Pakpimol, Pichyangkul Sathit, Hirunpetcharat Chakrit

机构信息

Department of Microbiology, Mahidol University, Bangkok, Thailand.

出版信息

Clin Vaccine Immunol. 2007 Apr;14(4):342-7. doi: 10.1128/CVI.00397-06. Epub 2007 Feb 21.

DOI:10.1128/CVI.00397-06
PMID:17314232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1865617/
Abstract

Merozoite surface protein 1 (MSP1) is the major protein on the surface of the plasmodial merozoite, and its carboxy terminus, the 19-kDa fragment (MSP1(19)), is highly conserved and effective in induction of a protective immune response against malaria parasite infection in mice and monkeys. However, the duration of the immune response has not been elucidated. As such, we immunized BALB/c mice with a standard four-dose injection of recombinant Plasmodium yoelii MSP1(19) formulated with Montanide ISA51 and CpG oligodeoxynucleotide (ODN) and monitored the MSP1(19)-specific antibody levels for up to 12 months. The antibody titers persisted constantly over the period of time without significant waning, in contrast to the antibody levels induced by immunization with Freund's adjuvant, where the antibody levels gradually declined to significantly lower levels 12 months after immunization. Investigation of immunoglobulin G (IgG) subclass longevity revealed that only the IgG1 antibody level (Th2 type-driven response) decreased significantly by 6 months, while the IgG2a antibody level (Th1 type-driven response) did not change over the 12 months after immunization, but the boosting effect was seen in the IgG1 antibody responses but not in the IgG2a antibody responses. After challenge infection, all immunized mice survived with negligibly patent parasitemia. These findings suggest that protective immune responses to MSP1(19) following immunization using oil-based Montanide ISA51 and CpG ODN as an adjuvant are very long-lasting and encourage clinical trials for malaria vaccine development.

摘要

裂殖子表面蛋白1(MSP1)是疟原虫裂殖子表面的主要蛋白,其羧基末端,即19-kDa片段(MSP1(19))高度保守,能有效诱导小鼠和猴子产生针对疟原虫感染的保护性免疫反应。然而,免疫反应的持续时间尚未阐明。因此,我们用含有Montanide ISA51和CpG寡脱氧核苷酸(ODN)配制的重组约氏疟原虫MSP1(19)对BALB/c小鼠进行标准的四剂注射免疫,并监测MSP1(19)特异性抗体水平长达12个月。与用弗氏佐剂免疫诱导的抗体水平不同,抗体滴度在这段时间内持续稳定,没有明显下降,后者在免疫12个月后抗体水平逐渐下降到显著更低的水平。对免疫球蛋白G(IgG)亚类持久性的研究表明,只有IgG1抗体水平(由Th2型驱动的反应)在6个月时显著下降,而IgG2a抗体水平(由Th1型驱动的反应)在免疫后的12个月内没有变化,但在IgG1抗体反应中观察到增强效应,而在IgG2a抗体反应中未观察到。攻击感染后,所有免疫小鼠存活,疟原虫血症可忽略不计。这些发现表明,使用油包水型Montanide ISA51和CpG ODN作为佐剂免疫后对MSP1(19)的保护性免疫反应非常持久,并鼓励开展疟疾疫苗开发的临床试验。